Immediate Impact
5 standout
Citing Papers
Remibrutinib in Chronic Spontaneous Urticaria
2025 Standout
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
2024 Standout
Works of Warner Carr being referenced
Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks
2023
Development and validation of a predictive model algorithm to identify anaphylaxis in adults with type 2 diabetes in U.S. administrative claims data
2021
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Warner Carr | 85 | 66 | 31 | 18 | 128 | |
| Antonio Di Marco | 88 | 92 | 20 | 17 | 188 | |
| Monica Carbonara | 123 | 113 | 42 | 18 | 222 | |
| Ayşe Süleyman | 74 | 31 | 48 | 24 | 174 | |
| Andrzej Dyczek | 122 | 62 | 23 | 15 | 197 | |
| C.A. Celis-Preciado | 147 | 93 | 52 | 17 | 198 | |
| Jeffrey Leflein | 187 | 146 | 81 | 16 | 240 | |
| Carole Guillet | 20 | 45 | 9 | 21 | 168 | |
| Eliana Toledo | 29 | 25 | 11 | 13 | 128 | |
| Jacek Musiał | 45 | 23 | 10 | 18 | 168 | |
| Johannes A. Kroes | 171 | 135 | 54 | 13 | 208 |
All Works
Loading papers...